Literature DB >> 11117482

Lewy body variant of Alzheimer's disease: alpha-synuclein in dystrophic neurites of A beta plaques.

O Wirths1, S Weickert, K Majtenyi, L Havas, P J Kahle, M Okochi, C Haass, G Multhaup, K Beyreuther, T A Bayer.   

Abstract

The contribution of alpha-synuclein accumulation in Alzheimer's disease (AD) plaques is currently a matter of scientific debate. In the present study antisera against the N- and C-terminus, the full-length protein and the central so-called non-amyloid component (NAC) domain of the alpha-synuclein protein were used to address this question in brains of cases with typical AD and of cases with the Lewy body (LB) variant of AD. In typical AD cases, none of the antisera revealed evidence for co-accumulation of alpha-synuclein with extracellular A beta peptides in plaques or in dystrophic neurites decorating the plaque core. Interestingly, cases with mixed pathology of the LB variant of AD revealed accumulation of alpha-synuclein in LBs and in dystrophic neurites of A beta plaques.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11117482     DOI： 10.1097/00001756-200011270-00029

Source DB:  PubMed          Journal:  Neuroreport        ISSN： 0959-4965            Impact factor:   1.837


  16 in total

1.  Insoluble alpha-synuclein in Alzheimer's disease without Lewy body formation.

Authors:  Melissa Broe; Claire E Shepherd; David M A Mann; Elizabeth A Milward; Wei-Ping Gai; Emma Thiel; Glenda M Halliday
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

2.  Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample.

Authors:  Willa D Brenowitz; Rebecca A Hubbard; C Dirk Keene; Stephen E Hawes; W T Longstreth; Randy L Woltjer; Walter A Kukull
Journal:  Alzheimers Dement       Date:  2016-11-19       Impact factor: 21.566

3.  Aβ Plaques.

Authors:  Lary C Walker
Journal:  Free Neuropathol       Date:  2020-10-30

4.  Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples.

Authors:  Willa D Brenowitz; C Dirk Keene; Stephen E Hawes; Rebecca A Hubbard; W T Longstreth; Randy L Woltjer; Paul K Crane; Eric B Larson; Walter A Kukull
Journal:  Neurobiol Aging       Date:  2017-01-30       Impact factor: 4.673

5.  Transglutaminase activation in neurodegenerative diseases.

Authors:  Thomas M Jeitner; Nancy A Muma; Kevin P Battaile; Arthur Jl Cooper
Journal:  Future Neurol       Date:  2009-07-01

6.  Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease.

Authors:  Marta Swirski; J Scott Miners; Rohan de Silva; Tammaryn Lashley; Helen Ling; Janice Holton; Tamas Revesz; Seth Love
Journal:  Alzheimers Res Ther       Date:  2014-12-01       Impact factor: 6.982

Review 7.  Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies.

Authors:  Rimona S Weil; Tammaryn L Lashley; Jose Bras; Anette E Schrag; Jonathan M Schott
Journal:  F1000Res       Date:  2017-08-30

8.  Axonal degeneration in an Alzheimer mouse model is PS1 gene dose dependent and linked to intraneuronal Aβ accumulation.

Authors:  Ditte Z Christensen; Melanie Huettenrauch; Miso Mitkovski; Laurent Pradier; Oliver Wirths
Journal:  Front Aging Neurosci       Date:  2014-06-27       Impact factor: 5.750

Review 9.  The Synaptic Function of α-Synuclein.

Authors:  Jacqueline Burré
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

10.  Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors.

Authors:  Anthony R Braun; Elly E Liao; Mian Horvath; Prakriti Kalra; Karen Acosta; Malaney C Young; Noah Nathan Kochen; Chih Hung Lo; Roland Brown; Michael D Evans; William C K Pomerantz; Elizabeth Rhoades; Kelvin Luk; Razvan L Cornea; David D Thomas; Jonathan N Sachs
Journal:  NPJ Parkinsons Dis       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.